Physicians' Academy for Cardiovascular Education

Kidney disease & CVD

Follow the news, literature, and elearning on new developments in the management of Kidney disease and CVD

Where do GLP-1RA fit in in current and future management of CKD?

10' education - July 26, 2021 - Frederik Persson, MD - Online CME

Treatment goals for patients with T2DM and CKD

10' education - July 13, 2021 - Prof. Peter Rossing, MD - Online CME

How can GLP-1RA benefit a patient with diabetes and CKD?

10' education - July 1, 2021 - Daniël van Raalte, MD, PhD - Online CME

Practical challenges with SGLT2i therapy in patients with T2DM and CKD

10' education - June 29, 2021 - Alice Cheng, MD - Online CME

Prevention strategies in patients with CKD and T2DM

10' education - June 24, 2021 - Ofri Mosenzon, MD - Online CME

Clinical inertia in CKD - What is the rationale for SGLT2i?

10' education - June 21, 2021 - Janaka Karalliedde, MD, PhD - Online CME

Kidney benefit by SGLT2i may be mediated by hematocrit

5' education - June 14, 2021 - Prof. Christoph Wanner, MD

Head-to-head comparison of risk scores for ischemic stroke in patients with AF and CKD

5' education - June 14, 2001 - Ype de Jong, MD

Prognostic value of natriuretic peptides in patients with HF and kidney dysfunction

10' education - May 11, 2021 - Prof. James Januzzi, MD

Effects of iron deficiency on outcomes in HF

10' education - Apr. 6, 2021 - Adrian F. Hernandez, MD

Reduction in albuminuria predicts future benefits on CV and renal outcomes in T2DM

10' education - Feb. 22, 2021 - Frederik Persson, MD

SGLT2 inhibitor is kidney protective, even if eGFR <30

3' education - Jan. 26, 2021 - Prof. George Bakris, MD

Novel findings with dual SGLT1 and SGLT2 inhibitor in diabetes patients

5' education - Nov. 23, 2020 - Prof. Deepak Bhatt, MD

SGLT2 inhibitors: a new foundation in heart failure or another diuretic?

10' education - Sep. 1, 2020 - Prof. Rudolf de Boer, MD, PhD

Nephroprotective effects with SGLT2i in CKD patients

3' education - Aug. 30, 2020 - Prof. Hiddo Heerspink, PhD

Targeting kidney outcomes in DKD: Can GLP-1RA provide kidney protection?

10' education - July 21, 2020 - Prof. Johannes Mann, MD

Targeting cardiovascular and kidney outcomes in CKD: Where do we stand today?

10' education - July 14, 2020 - Prof. Christoph Wanner, MD

Diabetes and CKD: is it all about managing glucose?

10' education - July 1, 2020 - Prof. Melanie Davies, MD

The cardiorenal connection and diabetes: Exploring intervention by SGLT2i

10' education - June 23, 2020 - Maria Rosa Costanzo, MD

No major effect of eGFR dip on reduction of incident or worsening nephropathy by SGLT2i

5' education - June 11, 2020 - Bettina Kraus, MD

Kidney protection and SGLT2i: What do we know?

10' education - June 9, 2020 - Prof. Mark Cooper, MD

Invasive vs. conservative strategy does not reduce CV events in patients with CKD and ischemia

3' education - Nov. 17, 2019 - Sripal Bangalore, MD, New york - AHA 2019, Philadelphia

Heart & Kidney interactions: What are the challenges for prevention and protection?

10' education - Sep. 2, 2019 - Prof. Christoph Wanner

The role of ALP as predictor of CV events and vascular calcification in CKD

10' education - June 15, 2019 - Dr. Mathias Haarhaus, MD

Underlying mechanisms of nephroprotective effects with SGLT2i in CKD

10' education - June 14, 2019 - ERA-EDTA 2019 - Paola Fioretto, MD - Online CME

The clinical landscape of managing patients with CKD: Where are we now and what can we expect?

10' education - June 14, 2019 - ERA-EDTA 2019 - Will Herrington, MD - Online CME

Clinical outcomes of GLP-1RA in kidney disease: Current evidence and ongoing trials

10' education - July 12, 2019 - ERA-EDTA 2019 - Frederik Persson, MD - Online CME

Epigenetic mechanisms targeting ALP: A pathway for prevention of vascular calcification?

10' education - Aug. 7, 2019 - Marta Ruiz-Ortega, PhD

RAAS inhibition in patients with kidney disease: Balancing the benefits and risks

10' education - July 12, 2019 - ERA-EDTA 2019 - Prof. Patrick Rossignol, MD - Online CME

Outcomes of SGLT2i in Diabetic Kidney Disease: Is it all diabetes?

10' education - July 4, 2019 - ERA-EDTA 2019 - Rajiv Agarwal, MD - Online CME

Where do GLP-1RA fit in in current and future management of CKD?

Subtitling in English, German, Italian, Spanish and French

10' education - July 26, 2021 - Frederik Persson, MD - Online CME
Besides current recommendations of GLP-1RA therapy for patients with T2DM and comorbidities, Frederik Persson discusses future possibilities for use of GLP-1RA in other target populations.

Besides current recommendations of GLP-1RA therapy for patients with T2DM and comorbidities to reduce CV events, Frederik Persson discusses future possibilities for use of GLP-1RA. With question to test your knowledge.

Suboptimal use of evidence-based medical therapies in patients with HFrEF and CKD

Literature - July 14, 2021 - Patel RB et al. - J Am Coll Cardiol. 2021

This study showed that prescription rates of evidence-based medical therapies are suboptimal in patients with comorbid HFrEF and CKD, even at eGFR levels where therapies are not contraindicated by kidney dysfunction.

Treatment goals for patients with T2DM and CKD

Subtitling in English, German, Italian, Spanish and French

10' education - July 13, 2021 - Prof. Peter Rossing, MD - Online CME
Prof. Rossing talks about setting treatment goals for patients with T2DM and CKD. These treatment goals are not limited to risk factor control but are also focused on organ protection.

Prof. Rossing talks about setting treatment goals for patients with T2DM and CKD. These treatment goals are not limited to risk factor control but are also focused on organ protection.

High-dose IV iron decreases occurrence of first and recurrent HF events in patients on hemodialysis

Literature - July 12, 2021 - Jhund PS et al. - JACC Heart Fail. 2021

This analysis of the PIVOTAL trial showed that treatment with high-dose IV iron administered proactively, compared to low-dose IV iron administered reactively, decreased the occurrence of first and recurrent HF events in patients receiving hemodialysis.

E-learning SGLT2i in CKD: How to overcome clinical inertia?

Accredited E-Learning

Online-CME - This course consists of 3 parts.
This course consists of 3 parts.

In this e-learning program, three experts discuss outcomes of relevant trials and guidelines that provide evidence and recommendations for using SGLT2i to improve outcomes in patients with CKD.

How can GLP-1RA benefit a patient with diabetes and CKD?

Subtitling in English, German, Italian, Spanish and French

10' education - July 1, 2021 - Daniël van Raalte, MD, PhD - Online CME
There is a need for therapies for patients with low eGFR. Daniël van Raalte discusses whether GLP-1RA therapy can provide benefit for patients with T2DM and CKD.

There is a need for therapies for patients with low eGFR. Daniël van Raalte discusses whether GLP-1RA therapy can provide benefit for patients with T2DM and CKD. With question to test your knowledge.

Early ARNI treatment initiation after acute decompensated HF well tolerated in HFrEF patients with CKD

News - June 30, 2021

ESC HF 2021 This post hoc analysis of the TRANSITION study demonstrated that early initiation and up-titration of sacubitril/valsartan after acute decompensated HF was well tolerated in HFrEF patients with CKD.

Nonsteroidal MRA reduces CV and kidney outcomes in CKD and T2DM irrespective of HF status

News - June 30, 2021

ESC HF 2021 A subanalysis of FIDELIO-DKD showed that finerenone lowered CV and kidney outcomes compared to placebo in patients with T2DM and CKD irrespective of pre-existing HF status.

SGLT2i in routine clinical practice reduces CV and renal events compared to DPP-4i in T2DM

News - June 29, 2021

ESC HF 2021 Use of empagliflozin was associated with reduced risk of CV and renal events, and all-cause mortality compared to use of DPP-4i in T2DM patients in a real world setting.

Practical challenges with SGLT2i therapy in patients with T2DM and CKD

10' education - June 29, 2021 - Alice Cheng, MD - Online CME
What are practical challenges around initiation of SGLT2i therapy? What should a physician explain to a patient at the start of SGLT2i therapy? Alice Cheng answers these questions in this video.

What are practical challenges around initiation of SGLT2i therapy? What should a physician explain to a patient at the start of SGLT2i therapy? Alice Cheng answers these questions in this video. With question to test your knowledge.

Prevention strategies in patients with CKD and T2DM

Subtitling in English, German, Italian, Spanish and French

10' education - June 24, 2021 - Ofri Mosenzon, MD - Online CME
Ofri Mosenzon discusses the importance of identification of CKD and how to prevent CKD progression in T2DM with older and newer therapeutic options.

Ofri Mosenzon discusses the importance of identification of CKD and how to prevent CKD progression in T2DM with older and newer therapeutic options. With question to test your knowledge.

E-learning GLP-1RA in DKD: A new preventive challenge

Accredited E-Learning

Online-CME - This course consists of 3 parts.
This course consists of 3 parts.

This e-learning program consists of three expert discussions in which management of patients with CKD is discussed.